Logo image of ARMP

ARMATA PHARMACEUTICALS INC (ARMP) Stock Fundamental Analysis

NYSEARCA:ARMP - NYSE Arca - US04216R1023 - Common Stock - Currency: USD

2.25  -0.12 (-5.06%)

Premarket: 2.24 -0.01 (-0.44%)

Fundamental Rating

1

Taking everything into account, ARMP scores 1 out of 10 in our fundamental rating. ARMP was compared to 561 industry peers in the Biotechnology industry. ARMP has a bad profitability rating. Also its financial health evaluation is rather negative. ARMP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ARMP has reported negative net income.
In the past year ARMP has reported a negative cash flow from operations.
In the past 5 years ARMP always reported negative net income.
ARMP had a negative operating cash flow in each of the past 5 years.
ARMP Yearly Net Income VS EBIT VS OCF VS FCFARMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

ARMP's Return On Assets of -21.88% is fine compared to the rest of the industry. ARMP outperforms 76.65% of its industry peers.
Industry RankSector Rank
ROA -21.88%
ROE N/A
ROIC N/A
ROA(3y)-43.53%
ROA(5y)-43.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARMP Yearly ROA, ROE, ROICARMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARMP Yearly Profit, Operating, Gross MarginsARMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

ARMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARMP has about the same amount of shares outstanding.
ARMP has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ARMP has a worse debt to assets ratio.
ARMP Yearly Shares OutstandingARMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ARMP Yearly Total Debt VS Total AssetsARMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ARMP has an Altman-Z score of -7.02. This is a bad value and indicates that ARMP is not financially healthy and even has some risk of bankruptcy.
ARMP's Altman-Z score of -7.02 is on the low side compared to the rest of the industry. ARMP is outperformed by 68.09% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.02
ROIC/WACCN/A
WACC9.04%
ARMP Yearly LT Debt VS Equity VS FCFARMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

ARMP has a Current Ratio of 0.23. This is a bad value and indicates that ARMP is not financially healthy enough and could expect problems in meeting its short term obligations.
ARMP has a worse Current ratio (0.23) than 95.90% of its industry peers.
A Quick Ratio of 0.23 indicates that ARMP may have some problems paying its short term obligations.
With a Quick ratio value of 0.23, ARMP is not doing good in the industry: 95.72% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.23
Quick Ratio 0.23
ARMP Yearly Current Assets VS Current LiabilitesARMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.11% over the past year.
The Revenue has grown by 14.01% in the past year. This is quite good.
Measured over the past years, ARMP shows a small growth in Revenue. The Revenue has been growing by 5.00% on average per year.
EPS 1Y (TTM)71.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112.73%
Revenue 1Y (TTM)14.01%
Revenue growth 3Y5%
Revenue growth 5YN/A
Sales Q2Q%-19.18%

3.2 Future

Based on estimates for the next years, ARMP will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.20% on average per year.
The Revenue is expected to grow by 78.86% on average over the next years. This is a very strong growth
EPS Next Y-280.54%
EPS Next 2Y-26.83%
EPS Next 3Y4.37%
EPS Next 5Y16.2%
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.46%
Revenue Next 5Y78.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ARMP Yearly Revenue VS EstimatesARMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 2027 2028 10M 20M 30M 40M 50M
ARMP Yearly EPS VS EstimatesARMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 200 -200 400 600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARMP. In the last year negative earnings were reported.
Also next year ARMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARMP Price Earnings VS Forward Price EarningsARMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARMP Per share dataARMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.83%
EPS Next 3Y4.37%

More info and screens

0

5. Dividend

5.1 Amount

ARMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARMATA PHARMACEUTICALS INC

NYSEARCA:ARMP (5/20/2025, 8:04:00 PM)

Premarket: 2.24 -0.01 (-0.44%)

2.25

-0.12 (-5.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners3.84%
Inst Owner Change-46.69%
Ins Owners0.75%
Ins Owner Change0%
Market Cap81.43M
Analysts82.86
Price Target7.14 (217.33%)
Short Float %0.07%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)83.54%
Min EPS beat(2)47.48%
Max EPS beat(2)119.61%
EPS beat(4)3
Avg EPS beat(4)51.14%
Min EPS beat(4)-118.22%
Max EPS beat(4)155.7%
EPS beat(8)4
Avg EPS beat(8)8.08%
EPS beat(12)5
Avg EPS beat(12)2.22%
EPS beat(16)9
Avg EPS beat(16)5.5%
Revenue beat(2)1
Avg Revenue beat(2)100.74%
Min Revenue beat(2)-22.38%
Max Revenue beat(2)223.86%
Revenue beat(4)1
Avg Revenue beat(4)21.89%
Min Revenue beat(4)-100%
Max Revenue beat(4)223.86%
Revenue beat(8)3
Avg Revenue beat(8)10.57%
Revenue beat(12)5
Avg Revenue beat(12)9.37%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-65.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-1.98
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0.14
BVpS-1.33
TBVpS-1.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.53%
ROA(5y)-43.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 141.81%
Cap/Sales 36.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.23
Quick Ratio 0.23
Altman-Z -7.02
F-Score4
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)409.33%
Cap/Depr(5y)282.59%
Cap/Sales(3y)85.41%
Cap/Sales(5y)77.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112.73%
EPS Next Y-280.54%
EPS Next 2Y-26.83%
EPS Next 3Y4.37%
EPS Next 5Y16.2%
Revenue 1Y (TTM)14.01%
Revenue growth 3Y5%
Revenue growth 5YN/A
Sales Q2Q%-19.18%
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.46%
Revenue Next 5Y78.86%
EBIT growth 1Y-3.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.52%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.82%
OCF growth 3YN/A
OCF growth 5YN/A